Species differences in the formation of vabicaserin carbamoyl glucuronide.
Vabicaserin is a potent 5-hydroxtryptamine 2C full agonist with therapeutic potential for a wide array of psychiatric disorders. Metabolite profiles indicated that vabicaserin was extensively metabolized via carbamoyl glucuronidation after oral administration in humans. In the present study, the differences in the extent of vabicaserin carbamoyl glucuronide (CG) formation in humans and in animals used for safety assessment were investigated. After oral dosing, the systemic exposure ratios of CG to vabicaserin were approximately 12 and up to 29 in monkeys and humans, respectively, and the ratios of CG to vabicaserin were approximately 1.5 and 1.7 in mice and dogs, respectively. These differences in systemic levels of CG are likely related to species differences in the rate and extent of CG formation and elimination. Whereas CG was the predominant circulating metabolite in humans and a major metabolite in mice, dogs, and monkeys, it was a relatively minor metabolite in rats, in which oxidative metabolism was the major metabolic pathway. Although the CG was not detected in plasma or urine of rats, approximately 5% of the dose was excreted in bile as CG in the 24-h collection postdose, indicating the rat had the metabolic capability of producing the CG. In vitro, in a CO(2)-enriched environment, the CG was the predominant metabolite in dog and human liver microsomes, a major metabolite in monkey and mice, and only a very minor metabolite in rats. Carbamoyl glucuronidation and hydroxylation had similar contributions to vabicaserin metabolism in mouse and monkey liver microsomes. However, only trace amounts of CG were formed in rat liver microsomes, and other metabolites were more prominent than the CG. In conclusion, significant differences in the extent of formation of the CG were observed among the various species examined. The exposure ratios of CG to vabicaserin were highest in humans, followed by monkeys, then mice and dogs, and lowest in rats, and the in vitro metabolite profiles generally correlated well with the in vivo metabolites.
Tong
Zeen
Z
Pfizer Inc., Collegeville, PA 19426, USA.
Chandrasekaran
Appavu
A
DeMaio
William
W
Jordan
Ronald
R
Li
Hongshan
H
Moore
Robin
R
Poola
Nagaraju
N
Burghart
Peter
P
Hultin
Theresa
T
Scatina
JoAnn
J
D000328:Adult; D000818:Animals; D019540:Area Under Curve; D001381:Azepines / Q000493:pharmacokinetics*; D001711:Biotransformation; D002851:Chromatography, High Pressure Liquid; D004285:Dogs; D004311:Double-Blind Method; D005260:Female; D020719:Glucuronides / Q000493:pharmacokinetics*; D006576:Heterocyclic Compounds, 4 or More Rings / Q000493:pharmacokinetics*; D006801:Humans; D066298:In Vitro Techniques; D008252:Macaca fascicularis; D008297:Male; D051379:Mice; D008862:Microsomes, Liver; D051381:Rats; D017207:Rats, Sprague-Dawley; D017366:Serotonin Receptor Agonists / Q000493:pharmacokinetics*; D013045:Species Specificity; D013056:Spectrophotometry, Ultraviolet
D001381:Azepines; D020719:Glucuronides; D006576:Heterocyclic Compounds, 4 or More Rings; D017366:Serotonin Receptor Agonists; C550333:vabicaserin carbamoyl glucuronide; C556517:vabicaserin